Precision Signals
Precision Signals
Podcast Description
Precision Signals is a podcast from the CEO Roundtable on Cancer about decoding biomedical progress: what’s real, what matters, and what’s next. We talk with scientists, regulators, investors, and builders operating across the messy interface of research, healthcare, and policy. Some are moving the system from within; others are reshaping it from the outside. All of them bring signal in a world crowded with noise.
Podcast Insights
Content Themes
The podcast covers critical topics related to biomedical research, healthcare systems, and regulatory frameworks. Episodes like 'The Mission is the Boss' focus on the challenges in clinical trials, discussing the journey of innovators like Dr. Michelle Longmire, while another episode, 'AI in Oncology: Hype, Evidence, and the Threshold of Clinical Trust', dives into the critical necessity of randomized trials for AI adoption in cancer care, illustrating the intricate balance between innovation and practical application.
Precision Signals is a podcast from the CEO Roundtable on Cancer about decoding biomedical progress: what’s real, what matters, and what’s next. We talk with scientists, regulators, investors, and builders operating across the messy interface of research, healthcare, and policy. Some are moving the system from within; others are reshaping it from the outside. All of them bring signal in a world crowded with noise.
In the latest episode of Precision Signals, Sean Khozin speaks with Peter Kolchinsky, founder and managing partner of RA Capital Management.
Peter’s perspective is shaped in part by his experience as the child of Soviet Jewish immigrants. His parents brought him a deep appreciation for education, hard work, entrepreneurship, and the opportunity to improve the systems around us.
That mindset has guided his journey from scientist and virologist to biotech investor and institution builder.
In this wide-ranging conversation, Sean and Peter discuss:
• How Peter moved from studying biology to helping scientists translate discoveries into medicines
• Why the biotech industry needs stronger institutional memory, including a willingness to learn from failed experiments
• The limitations of AI in drug development, where generating a promising molecule is only the beginning of a years-long clinical learning process
• Why China’s expanding clinical trial infrastructure may have a greater near-term impact on the pace of R&D than AI
• How the FDA can be understood as a community of people working within a complex institution, rather than as an opaque gatekeeper
• Why CEOs must define their role by what it takes to advance the mission, including advocacy for patients, innovation, and better policy
A substantive discussion about immigration, science, entrepreneurship, AI, clinical trials, regulation, and what it means to build organizations that keep learning.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.